{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:04:33Z","timestamp":1794917073387,"version":"4.9.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY026877"],"award-info":[{"award-number":["EY026877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajo.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:03:24Z","timestamp":1747163004000},"page":"57-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and Safety of Biologics in Pediatric Noninfectious Retinal Vasculitis"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-0887","authenticated-orcid":false,"given":"Irmak","family":"Karaca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3275-7537","authenticated-orcid":false,"given":"Zheng Xian","family":"Thng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-6369","authenticated-orcid":false,"given":"Albert","family":"Bromeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Mobasserian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Akhavanrezayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6123-675X","authenticated-orcid":false,"given":"Ngoc Trong Tuong","family":"Than","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Yasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-2935","authenticated-orcid":false,"given":"Negin","family":"Yavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"El Feky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Elaraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Ngoc Tram","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-6840","authenticated-orcid":false,"given":"Aim-On","family":"Saengsirinavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances Andrea","family":"Anover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Mong Christopher","family":"Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0001","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.survophthal.2021.06.006","article-title":"Pediatric uveitis: a comprehensive review","volume":"67","author":"Maleki","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2025.05.002_bib0002","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.ophtha.2009.05.002","article-title":"Epidemiology and course of disease in childhood uveitis","volume":"116","author":"Smith","year":"2009","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2025.05.002_bib0003","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/BOR.0000000000000316","article-title":"Uveitis in children","volume":"28","author":"ST","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.ajo.2025.05.002_bib0004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/09273948.2017.1420202","article-title":"The challenge of pediatric uveitis: tertiary referral center experience in the United States","volume":"27","author":"Ferrara","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.ajo.2025.05.002_bib0005","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/IAE.0000000000002885","article-title":"Retinal vasculitis, a common manifestation of idiopathic pediatric uveitis?","volume":"41","author":"Yang","year":"2021","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0006","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.oret.2019.09.007","article-title":"The detection of occult retinal vasculitis on fluorescein angiography in pediatric uveitis","volume":"4","author":"Abraham","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.002_bib0007","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/09273948.2020.1834586","article-title":"Widefield fundus fluorescein angiography features of uveitis associated with juvenile idiopathic arthritis","volume":"30","author":"Tripathy","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.ajo.2025.05.002_bib0008","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/09273948.2023.2168697","article-title":"wide-field fluorescein angiography in patients with idiopathic acute anterior uveitis","volume":"32","author":"Yagci","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.ajo.2025.05.002_bib0009","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10792-009-9301-3","article-title":"A clinical approach to the diagnosis of retinal vasculitis","volume":"30","author":"El-Asrar","year":"2010","journal-title":"Int Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.002_bib0011","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.icu.0000144386.05116.c5","article-title":"Imaging techniques for posterior uveitis","volume":"15","author":"Ciardella","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.05.002_bib0012","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10792-008-9263-x","article-title":"Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis)","volume":"30","author":"Tugal-Tutkun","year":"2010","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajo.2025.05.002_bib0013","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ajo.2024.04.016","article-title":"Importance of baseline fluorescein angiography for patients presenting to tertiary uveitis clinic","volume":"265","author":"Karaca","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.05.002_bib0014","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00417-014-2637-z","article-title":"Long-term progression of retinal vasculitis in Behcet patients using a fluorescein angiography scoring system","volume":"252","author":"Kang","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0016","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10792-017-0487-5","article-title":"Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease","volume":"38","author":"Balci","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajo.2025.05.002_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40942-020-00245-w","article-title":"Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study","volume":"6","author":"Sadiq","year":"2020","journal-title":"Int J Retina Vitreous"},{"issue":"11","key":"10.1016\/j.ajo.2025.05.002_bib0018","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41433-022-02315-9","article-title":"Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis","volume":"37","author":"Karaca","year":"2023","journal-title":"Eye (Lond)"},{"issue":"17","key":"10.1016\/j.ajo.2025.05.002_bib0019","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajo.2025.05.002_bib0020","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.002_bib0021","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1097\/RHU.0000000000001707","article-title":"Weekly adalimumab, an effective alternative for refractory uveitis in children","volume":"28","author":"Roberts","year":"2022","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0022","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10067-017-3890-4","article-title":"Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis","volume":"37","author":"Correll","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.002_bib0023","doi-asserted-by":"crossref","first-page":"e994","DOI":"10.1111\/aos.15012","article-title":"Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis","volume":"100","author":"Kouwenberg","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0024","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00417-021-05398-4","article-title":"Clinical characteristics and treatment of pars planitis: an adalimumab experience","volume":"260","author":"Ozdemir","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2025.05.002_bib0025","article-title":"The efficacy and safety of adalimumab in treating pediatric noninfectious chronic anterior uveitis with peripheral retinal vascular leakage: a pilot study","volume":"9","author":"Song","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.002_bib0026","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jaapos.2008.08.007","article-title":"Retrospective analysis of children with uveitis treated with infliximab","volume":"12","author":"Tugal-Tutkun","year":"2008","journal-title":"J AAPOS"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.002_bib0027","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12969-019-0383-9","article-title":"Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis","volume":"17","author":"Miraldi Utz","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.ajo.2025.05.002_bib0028","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2022.06.024","article-title":"Alternative biologic therapy in children failing conventional TNFalpha inhibitors for refractory, noninfectious, chronic anterior uveitis","volume":"244","author":"Miraldi Utz","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0029","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10067-019-04763-3","article-title":"Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-alpha inhibition: a narrative review","volume":"39","author":"Gaggiano","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.ajo.2025.05.002_bib0030","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.002_bib0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/09273948.2020.1712431","article-title":"Tocilizumab as an effective treatment option in children with refractory intermediate and panuveitis","volume":"29","author":"Wennink","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"10.1016\/j.ajo.2025.05.002_bib0032","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"10.1016\/j.ajo.2025.05.002_bib0033","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajo.2025.05.002_bib0034","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.05.002_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.ajo.2025.05.002_bib0036","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","article-title":"Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial","volume":"207","author":"Horton","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.002_bib0037","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41433-018-0283-0","article-title":"Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis","volume":"33","author":"McCracken","year":"2019","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.002_bib0038","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/acr.23610","article-title":"Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.002_bib0039","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s40123-023-00712-1","article-title":"Efficacy and safety of adalimumab in pediatric non-infectious non-anterior uveitis: real-life experience from the International AIDA Network Uveitis Registry","volume":"12","author":"Vitale","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.002_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12348-019-0181-z","article-title":"Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis","volume":"9","author":"Ho","year":"2019","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0041","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/rheumatology\/keaa595","article-title":"Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis","volume":"60","author":"Maccora","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.002_bib0042","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ajo.2007.08.018","article-title":"Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up","volume":"144","author":"Ardoin","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.002_bib0043","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00417-018-3928-6","article-title":"The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies","volume":"256","author":"Deitch","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.05.002_bib0044","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","article-title":"Biological response modifier therapy for refractory childhood uveitis","volume":"91","author":"Gallagher","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.05.002_bib0045","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0046","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.002_bib0047","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semarthrit.2014.03.001","article-title":"Does switching anti-TNFalpha biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach","volume":"44","author":"Simonini","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ajo.2025.05.002_bib0048","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41433-023-02795-3","article-title":"Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy","volume":"38","author":"Kreps","year":"2024","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0049","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/09273948.2013.866254","article-title":"Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient","volume":"22","author":"Tsang","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.002_bib0050","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","article-title":"Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?","volume":"39","author":"Tappeiner","year":"2012","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.ajo.2025.05.002_bib0051","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3899\/jrheum.160231","article-title":"Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis","volume":"43","author":"Tappeiner","year":"2016","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.ajo.2025.05.002_bib0052","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients","volume":"69","author":"Calvo-Rio","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.002_bib0053","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/09273948.2020.1817501","article-title":"Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis","volume":"29","author":"Maleki","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"10.1016\/j.ajo.2025.05.002_bib0054","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1080\/09273948.2022.2161916","article-title":"Subcutaneous tocilizumab in juvenile idiopathic arthritis associated uveitis","volume":"31","author":"Marino","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2025.05.002_bib0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (month-6) outcomes of the STOP-Uveitis Study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.002_bib0056","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3899\/jrheum.160908","article-title":"Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis-associated uveitis","volume":"44","author":"Quesada-Masachs","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2025.05.002_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273948.2024.2354751","article-title":"Outcomes of intravenous tocilizumab treatment for refractory pars planitis","author":"Kongrat","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2025.05.002_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152153","article-title":"Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients","volume":"58","author":"Barroso-Garcia","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ajo.2025.05.002_bib0059","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-tumor necrosis factor alpha versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.05.002_bib0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","article-title":"Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients","volume":"200","author":"Vegas-Revenga","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.05.002_bib0061","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","article-title":"Safety of biologic therapies for the treatment of juvenile idiopathic arthritis","volume":"14","author":"Horneff","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.ajo.2025.05.002_bib0063","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ophtha.2023.07.023","article-title":"Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality","volume":"130","author":"Kempen","year":"2023","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:18:19Z","timestamp":1754918299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942500234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":62,"alternative-id":["S000293942500234X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.05.002","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Biologics in Pediatric Noninfectious Retinal Vasculitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}